Fox Jennifer's most recent trade in Myriad Genetics, Inc. was a trade of 63,145 Common Stock done . Disclosure was reported to the exchange on March 13, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Myriad Genetics, Inc. | Jennifer Fox | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 63,145 | 124,916 (0%) | 0% | 0 | Common Stock | |
ProKidney Corp - Ordinary ... | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 9,535 | 9,535 | - | - | Director stock option (right to buy) | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2024 | 15,000 | 186,382 (0%) | 0% | 0 | Common Stock | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.19 per share. | 08 Jun 2024 | 2,376 | 171,382 (0%) | 0% | 6.2 | 14,707 | Common Stock |
Apogee Therapeutics Inc. | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 10,370 | 10,370 | - | - | Stock Option (Right to Buy) | |
ProKidney Corp - Ordinary ... | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 62,558 | 62,558 | - | - | Director stock option (right to buy) | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 125,000 | 223,169 | - | - | Employee Stock Options (Right to Buy) | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.23 per share. | 29 Feb 2024 | 4,103 | 174,461 (0%) | 0% | 3.2 | 13,253 | Common Stock |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.39 per share. | 29 Feb 2024 | 703 | 173,758 (0%) | 0% | 3.4 | 2,383 | Common Stock |
Emergent Biosolutions Inc | Fox Jennifer | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.74 per share. | 23 Feb 2024 | 229 | 178,564 (0%) | 0% | 2.7 | 627 | Common Stock |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.00 per share. | 11 Nov 2023 | 413 | 178,793 (0%) | 0% | 2 | 826 | Common Stock |
ProKidney Corp - Ordinary ... | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2023 | 46,632 | 46,632 | - | - | Director stock option (right to buy) | |
ProKidney Corp - Ordinary ... | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2023 | 42,515 | 42,515 | - | - | Director stock option (right to buy) | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 49,231 | 98,169 | - | - | Employee Stock Option (Right to buy) | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 49,231 | 179,206 (0%) | 0% | 0 | Common Stock | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 24,616 | 129,975 (0%) | 0% | 0 | Common Stock | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 12,308 | 105,359 (0%) | 0% | 0 | Common Stock | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 12,308 | 48,938 | - | - | Employee Stock Options (Right to Buy) | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 6,154 | 93,051 (0%) | 0% | 0 | Common Stock | |
Nuvation Bio Inc - Ordinar... | Jennifer A. Fox | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.38 per share. | 28 Feb 2023 | 1,005 | 86,897 (0%) | 0% | 12.4 | 12,442 | Common Stock |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.71 per share. | 23 Feb 2023 | 258 | 87,902 (0%) | 0% | 13.7 | 3,537 | Common Stock |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.30 per share. | 23 Feb 2023 | 231 | 88,160 (0%) | 0% | 14.3 | 3,303 | Common Stock |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 42,135 | 88,391 (0%) | 0% | 0 | Common Stock | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 14,045 | 46,256 (0%) | 0% | 0 | Common Stock | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.00 per share. | 11 Nov 2022 | 416 | 32,211 (0%) | 0% | 15 | 6,240 | Common Stock |
ProKidney Corp - Ordinary ... | Jennifer A. Fox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Sep 2022 | 129,370 | 129,370 | - | - | Stock option (right to buy) | |
Nuvation Bio Inc - Ordinar... | Jennifer A. Fox | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2022 | 480,000 | 480,000 | - | - | Stock Option (Right to Buy) | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 26,584 | 26,584 | - | - | Employee Stock Options (Right to Buy) | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 17,794 | 32,627 (0%) | 0% | 0 | Common Stock | |
Emergent Biosolutions Inc | Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 7,583 | 14,833 (0%) | 0% | 0 | Common Stock | |
Nuvation Bio Inc - Ordinar... | Jennifer A. Fox | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) |